Management of patients with hereditary defects predisposing to thrombosis including pregnant women.
In general, the current recommendations for treating and prophylaxing thrombotic patients with hereditary defects are similar to those for thrombotic individuals without a defect. Determinations as to the need for long-term anticoagulation require that a clinical assessment be made regarding the relative benefit in preventing thrombotic episodes versus the risk of increased bleeding. With our newly found ability to identify genetic risk factors in a substantial fraction of patients with venous thrombosis and pulmonary embolism, it will be possible to perform rigorously designed studies to determine whether they should be managed with more prolonged or intense anticoagulation after a thrombotic event or more aggressive prophylactic regimens in high risk situations such as a total hip replacement.
Bauer
K A
KA
Hematology-Oncology Section, Brockton-West Roxbury Department of Veterans Affairs Medical Center, MA, USA.
D000014:Abnormalities, Drug-Induced / Q000517:prevention & control; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D000990:Antithrombin III / Q000235:genetics; D020152:Antithrombin III Deficiency; D001798:Blood Proteins / Q000172:deficiency* / Q000235:genetics; D003374:Coumarins / Q000009:adverse effects / Q000627:therapeutic use; D004198:Disease Susceptibility / Q000453:epidemiology; D003875:Drug Eruptions / Q000209:etiology / Q000628:therapy; D005166:Factor V Deficiency / Q000150:complications / Q000235:genetics; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009336:Necrosis; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000209:etiology / Q000517:prevention & control*; D015995:Prevalence; D011486:Protein C / Q000378:metabolism; D018455:Protein S Deficiency / Q000150:complications / Q000235:genetics; D011644:Puerperal Disorders / Q000235:genetics / Q000517:prevention & control; D011693:Purpura / Q000139:chemically induced / Q000628:therapy; D012008:Recurrence; D012306:Risk; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000235:genetics / Q000517:prevention & control*; D014859:Warfarin / Q000009:adverse effects
D000925:Anticoagulants; D001798:Blood Proteins; D003374:Coumarins; D005343:Fibrinolytic Agents; D011486:Protein C; D014859:Warfarin; D000990:Antithrombin III; C030123:coumarin